Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic … (NCT05457257) | Clinical Trial Compass
Active — Not RecruitingPhase 4
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
China43 participantsStarted 2022-07-29
Plain-language summary
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.
Who can participate
Age range18 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Histologically confirmed diagnosis of prostate cancer.
✓. Documented evidence of metastatic castration resistant prostate cancer (mCRPC).
✓. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC .
✓. Ongoing therapy with LHRH analog or bilateral orchiectomy.
✓. Radiological progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy).
✓. Deleterious or suspected deleterious BRCA1/2 mutation in tumor tissue.
✓. Normal organ and bone marrow function measured within 28 days prior to administration of study treatment.
✓. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
Exclusion criteria
✕. Any previous treatment with a poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor, including olaparib.
✕. Subjects who had any previous treatment with DNA-damaging cytotoxic chemotherapy, except if for non-prostate cancer indication and last dose \> 5 years prior to randomization.
✕. History of another primary malignancy except for malignancy treated with curative intent with no known active disease for ≥5 years before the first dose of study intervention and of low potential risk for recurrence.
What they're measuring
1
Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)
Timeframe: Tumor assessments every 8 weeks (± 1 week) relative to the date of randomization until radiological progression as assessed by BICR or death (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).
✕. Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.